Assignee
PROTEOSTASIS THERAPEUTICS INC
US23 patents
Top patents by PatentIndex Score
US10548878B2Feb 4, 2020
Compounds, compositions, and methods of increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC8 citations84
US10392372B2Aug 27, 2019
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC6 citations84
US10392378B2Aug 27, 2019
Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
PROTEOSTASIS THERAPEUTICS INC7 citations84
US10174014B2Jan 8, 2019
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC9 citations84
US10017503B2Jul 10, 2018
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC11 citations84
US9790219B2Oct 17, 2017
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC16 citations84
US9745292B2Aug 29, 2017
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC14 citations84
US9850262B2Dec 26, 2017
Proteasome activity enhancing compounds
PROTEOSTASIS THERAPEUTICS INC6 citations82
US10550106B2Feb 4, 2020
Compounds, compositions, and methods for modulating CFTR
PROTEOSTASIS THERAPEUTICS INC9 citations81
US10344023B2Jul 9, 2019
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
PROTEOSTASIS THERAPEUTICS INC6 citations73
US10662207B2May 26, 2020
Compounds, compositions, and methods for modulating CFTR
PROTEOSTASIS THERAPEUTICS INC4 citations72
US11242361B2Feb 8, 2022
Proteasome activity enhancing compounds
PROTEOSTASIS THERAPEUTICS INC2 citations71
US11248010B2Feb 15, 2022
Compounds, compositions, and methods for modulating CFTR
PROTEOSTASIS THERAPEUTICS INC0 citations62
US11098035B2Aug 24, 2021
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC0 citations62
US11083709B2Aug 10, 2021
Compounds, compositions, and methods of increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC0 citations62
US10738011B2Aug 11, 2020
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
PROTEOSTASIS THERAPEUTICS INC1 citations62
US10738040B2Aug 11, 2020
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC1 citations62
US11560385B2Jan 24, 2023
Proteasome activity enhancing compounds
PROTEOSTASIS THERAPEUTICS INC0 citations61
US10899751B2Jan 26, 2021
Compounds, compositions, and methods for increasing CFTR activity
PROTEOSTASIS THERAPEUTICS INC1 citations61
US11746098B2Sep 5, 2023
Proteasome activity enhancing compounds
PROTEOSTASIS THERAPEUTICS INC1 citations60
US11136313B2Oct 5, 2021
Compounds, compositions, and methods for modulating CFTR
PROTEOSTASIS THERAPEUTICS INC1 citations59
US10532996B2Jan 14, 2020
Proteostasis regulators
PROTEOSTASIS THERAPEUTICS INC0 citations50
US9399647B2Jul 26, 2016
Proteasome activity modulating compounds
PROTEOSTASIS THERAPEUTICS INC0 citations40